单克隆抗体治疗结直肠癌的数学模型
Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments
摘要:
我们提出了一个新的数学模型的结直肠癌生长和单克隆抗体(mAb)治疗的反应。尽管前景看好,但大多数mAb药物仍处于试验阶段,目前批准使用的药物给药方案的可能变化尚未得到彻底探索。为了研究当前mAb治疗方案的有效性,并测试假设的治疗策略,我们创建了一个非线性常微分方程(ODE)系统来模拟结直肠癌的生长和治疗。该模型包括肿瘤细胞,宿主免疫反应的元素和治疗。模型治疗包括化疗药物伊立替康和两种单克隆抗体之一-西妥昔单抗,这是FDA批准的结直肠癌,帕尼单抗,这仍在临床试验中进行评估。该模型结合了患者特定的参数,以解释免疫系统强度和抗肿瘤药物疗效的个体差异。我们已经模拟了治疗方案的虚拟患者组的临床试验数据,使用一系列生物学合理的患者特定参数值。我们的结果与这些方案的临床试验结果非常吻合。我们还模拟了实验给药方案,并发现了新的方案,在我们的模拟中,比目前的治疗方案更有效地减少肿瘤大小。此外,我们研究了系统的平衡和参数值的敏感性。在没有治疗的情况下,肿瘤演变最受内在肿瘤生长速率和携带能力的影响。当引入治疗时,肿瘤生长受药物特异性PK/PD参数的影响最大。
英文摘要:
We present a new mathematical model of colorectal cancer growth and its response to monoclonal-antibody (mAb) therapy. Although promising, most mAb drugs are still in trial phases, and the possible variations in the dosing schedules of those currently approved for use have not yet been thoroughly explored. To investigate the effectiveness of current mAb treatment schedules, and to test hypothetical treatment strategies, we have created a system of nonlinear ordinary differential equations (ODE) to model colorectal cancer growth and treatment. The model includes tumor cells, elements of the host's immune response, and treatments. Model treatments include the chemotherapy agent irinotecan and one of two monoclonal antibodies - cetuximab, which is FDA-approved for colorectal cancer, and panitumumab, which is still being evaluated in clinical trials. The model incorporates patient-specific parameters to account for individual variations in immune system strength and in medication efficacy against the tumor. We have simulated outcomes for groups of virtual patients on treatment protocols for which clinical trial data are available, using a range of biologically reasonable patient-specific parameter values. Our results closely match clinical trial results for these protocols. We also simulated experimental dosing schedules, and have found new schedules which, in our simulations, reduce tumor size more effectively than current treatment schedules. Additionally, we examined the system's equilibria and sensitivity to parameter values. In the absence of treatment, tumor evolution is most affected by the intrinsic tumor growth rate and carrying capacity. When treatment is introduced, tumor growth is most affected by drug-specific PK/PD parameters.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。